Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction

Abstract

Objective: Erectile dysfunction (ED) is a common condition in patients with heart failure (HF), which impairs quality of life. Our
 study aimed to compare those patients, who received traditional treatment with a diagnosis of HF and those who received angiotensin
 receptor-neprilysin inhibitor (ARNI) treatment in addition to the current treatment, in terms of ED at the end of 6 months.
 Patients and Methods: The study was planned as a single-center, prospective study. The study included 200 patients with heart
 failure. The patients’ demographic, clinical, and echocardiographic characteristics were recorded, and an international ED scoring
 questionnaire was applied. The participants in the study were divided into two groups: those who received ARNI treatment and those
 who did not. After 6 months, the ED questionnaire was applied to the patients again and the groups were compared.
 Results: The median age of the patients was 53 (years). The median ejection fraction (EF) value was calculated to be 30% and no
 significant difference was found between the groups (p: 0.122). It was found that N-terminal pro-brain natriuretic peptide (NT-pro-
 BNP) levels measured at the end of the 6th month were significantly lower in patients who had received ARNI treatment than in those
 who had not (respectively, 245 pg/ml, 200 pg/ml; p: 0.003). In the analysis performed to detect the presence of ED, it was discovered
 that the ED score change was significantly higher in the group that had received 6 months of ARNI treatment (p: 0.031) compared to
 that in the group that had not (p: 0.031). When the ED sub-parameters were compared in terms of the 6-month change rate, it was
 found that the ARNI group had a significant increase in terms of ED and sexual satisfaction scores, but no significant difference was
 found in the other parameters (p: 0.001, p: 0.029).
 Conclusion: Erectile dysfunction is more common in patients with heart failure compared to the rest of society and impairs quality of
 life. In our study, it was determined that ED complaints decreased significantly in HF patients, who had received ARNI treatment for
 6 months than in patients who had not.

The Impact of Heart Failure on Sexual Satisfaction of Sexual partners: A Cross-sectional Study in Iran

“…Ceyhun et al also addressed the relationship between ED and NT-pro-BNP in patients with chronic HF and observed a relationship between the increase in NT-pro-BNP and increased severity of ED. Similarly, another study showed that ED was more common in the non-ARNI group that had high NT-pro-BNP levels compared to the ARNI group that had received ARNI for 6 months and had low NT-pro-BNP levels (29,30).…”

Investigation of Potential cGMP-Specific PDE V and Aminopeptidase N Inhibitors of Allium ampeloprasum L. and Its Bioactive Components: Kinetic and Molecular Docking Studies

“…As the elderly male population experiencing menopausal symptoms increases, it is anticipated that there will be a rise in health expenditure and the emergence of various social issues [5,6]. A representative symptom of sexual dysfunction is erectile dysfunction (ED), and a commonly used treatment is using oral type 5 phosphodiesterase (PDE5) inhibitors such as sildenafil [7] and neprilysin (NEP) inhibitor [8]. The activities and functions of the heart and blood vessels are regulated by the interaction between cardiokines and cardiomyokines, which are specific cardiomyocytes-derived peptides [9,10].…”